Hiroshi Imaoka

14PUBLICATIONS
28CO-AUTHORS
Cancer diagnosisPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 12, 2026
Clinical Implications of Polyploid Giant Cancer Cells in Solid Tumors: Biology, Diagnosis, and Therapeutic Considerations.

|Mar 20, 2026
Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer.

Tomonao Taira, Tomoyuki Satake, Go Igarashi

|Mar 07, 2025
Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113.

Mao Okada, Eiichiro Suzuki, Chigusa Morizane

|Jan 29, 2025
Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.

Hiroshi Imaoka, Masafumi Ikeda, Satoshi Kobayashi

|Jan 08, 2025
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113.

Koh Fukushi, Hiroshi Imaoka, Masafumi Ikeda

|Nov 30, 2024
Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.

Hiroshi Imaoka, Masafumi Ikeda, Satoshi Kobayashi

Pageof 3

Frequent Collaborators

4 joint publications

Masafumi Ikeda

4 joint publications

Naohiro Okano

2 joint publications

Akiko Todaka

2 joint publications

Yasuyuki Kawamoto